Vitamin B3 as an adjuvant treatment in schizophrenia: a double-blind, randomized, controlled clinical trial

The clinical safety and efficacy evaluation of Vitamin B3 as an adjuvant treatment in schizophrenia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16008395

Enrollment

Unknown

Registered

2016-04-30

Start date

2016-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Vitamin B3 supplementary group:with vitamin B3 adjuvant therapy

Treat-as-usual Group:None

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Diagnosed as schizophrenia according to ICD-10; aged between 18 and 70; inpatients; with informed consent approved;

Exclusion criteria

Exclusion criteria: 1. Within 4 weeks before had participated in other clinical trials; 2. With diabetes, hypertension, gout, autoimmune diseases, neurological diseases, gastrointestinal diseases; 3. With mental symptoms of caused by alcohol or drug abuse or brain injury; 4. Allergic, suffered or are suffering from allergic skin disease; 5. Within two weeks before had taken aspirin and other non steroidal anti-inflammatory drugs, vitamins or lipid supplements; 6. With serious liver and kidney disease; 7. Alcohol or cigarette dependence; 8. Refusal to sign the informed consent form;

Design outcomes

Primary

Measure	Time frame
PANSS score;	—

Secondary

Measure	Time frame
CGI score;	—

Countries

China

Contacts

Public ContactChunling Wan

Shanghai Jiao Tong University

clwan@sjtu.edu.cn+86 13564485327

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026